Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells

作者：Cheng, Zhiyong; Fu, Jianzhu; Liu, Guimin; Zhang, Lijun; Xu, Qian; Wang, Su-yun^*

来源：Leukemia and Lymphoma, 2018, 59(1): 196-203.

DOI：10.1080/10428194.2017.1324155

• Myeloproliterative neoplasms
• ruxolitinib
• JAK2 V617F mutation
• VEGF
• HIF-1 alpha
• angiogenesis

Angiogenesis and JAK2 V617F mutation are common in BCR-ABL1 negative myeloproliferative neoplasms (MPNs). Ruxolitinib, a JAK inhibitor, is an effective treatment for some MPNs. However, the relationship between angiogenesis and JAK2 V617F and the effects of ruxolitinib on angiogenesis are still unknown. Here, we observed the correlation of JAK2 V617F mutation burden with VEGF, HIF-1 alpha and microvascular density (MVD) in MPNs. We investigate the effect of ruxolitinib on the expression of VEGF and HIF-1 alpha in JAK2 V617F positive cells. We found the expression levels of p-JAK2, VEGF, HIF-1 alpha and MVD in the newly diagnosed MPNs were significantly increased and were related to the JAK2 V617F burden. Ruxolitinib can inhibit p-JAK2, VEGF, HIF-1 alpha expression and suppress blood vessels' formation in chick embryo choriallantoic membrane. Our findings indicated that angiogenesis is related to JAK2 V617F burden and ruxolitinib could decrease VEGF and HIF-1 alpha expression in JAK2 V617F positive cells.

• 出版日期2018
• 单位河北省人民医院